Dengue vaccines: where are we now and where we are going?

Dengue, the main arboviral disease worldwide,1 is a disease of high epidemiological impact caused by serotypes 1, 2, 3, or 4 of dengue virus.2 At least 60 million symptomatic infections occur annually worldwide, resulting in about 10 000 deaths. More than 4 billion people are at risk in countries that present optimal conditions for Aedes spp mosquitoes—the key vector of dengue virus.3 Thus, the development of safe and effective dengue vaccines is a priority according to WHO.2 Only one tetravalent dengue vaccine, CYD-TDV (Dengvaxia; Sanofi Pasteur), has already been licensed in endemic countries.